Natco Pharma Approves ₹6/Share Dividend for FY25

Disclaimer This is an AI-assisted live blog with updates sourced from multiple news outlets and agencies Disclaimer

Natco Pharma's board has approved a dividend of ₹6 per equity share for the financial year 2024-25. The decision was made during the 42nd Annual General Meeting (AGM) held on September 25, 2025.

The AGM, conducted via video conference, saw the presence of key directors and shareholders. The meeting addressed various items, including the adoption of audited financial statements, the re-appointment of directors, and the approval of borrowing powers.

Key Highlights of the AGM:

• Adoption of audited Annual Financial Statements for the Financial Year 2024-25.
• Confirmation of three interim dividends aggregating to ₹6.00 per share paid on equity shares during the Financial Year 2024-25 as dividend for the FY 2024-25.
• Re-appointment of Sri Rajeev Nannapaneni as a Director liable to retire by rotation.
• Appointment of Secretarial Auditors.
• Ratification of remuneration of Cost Auditors.
• Approval of Borrowing Powers of the Company under Section 180(1)(c) of the Companies Act, 2013.
• Approval for the Creation of Charge(s) on the movable and immovable properties of the Company.
• Approval to increase the Authorized Share Capital of the Company.

The meeting was attended by 62 members via video conference, with key directors such as Sri V.C. Nannapaneni (Chairman & Managing Director) and Sri Rajeev Nannapaneni (Vice Chairman & CEO) present at the registered office. Other directors participated through video conference.

The proceedings of the AGM were conducted smoothly, with shareholders raising queries and comments that were addressed by the management. The results of the remote e-voting and e-voting during the AGM will be announced within two working days.